
    
      This study is a Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa study.
      All enrolled subjects will be given a single dose of 10 mg/kg CT-P27, 20 mg/kg CT-P27, or
      placebo intravenously and then followed by Day 36.
    
  